Business Wire

Exscientia Business Update for Third Quarter 2021

Share

Exscientia (Nasdaq: EXAI):

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117006300/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Recent advancements in the Company’s pipeline, collaborations and operations as well as financial results for the third quarter ended September 30, 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, November 18 at 1:30 p.m. GMT / 8:30 a.m. ET to provide detail on the business models underlying the Company’s pipeline of more than 25 programmes.

Highlights

Leveraging deep learning on patient tissue samples at scale to transform target discovery and patient selection

- Expanded investigation of patient tissue models in solid tumours, including ongoing analysis of EXS-617 in ovarian and breast cancer models

- Published EXALT-1 clinical trial results in Cancer Discovery that highlighted benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancer

- Completed acquisition of Allcyte, integrating leading tissue platform into Exscientia’s end-to-end drug discovery operations

Pipeline progress marked by candidate nomination, significant expansion of existing collaborations

- Partnered programmes

  • Expanded Bristol Myers Squibb collaboration to include potential targets across immunology and oncology; potential deal value beyond $1.3 billion
    • BMS in-licensed first candidate from original 2019 collaboration, a potential first-in-class immunology medicine, triggering $20.0 million option exercise fee

- Co-owned programmes

  • EXS-617: development candidate nominated for CDK7 inhibitor from expanded joint venture with GT Apeiron; additional translational data anticipated 1H 2022
  • First two targets selected in EQRx joint venture

- Wholly and majority owned programmes

  • EXS-21546: Phase 1 data for A2a antagonist in high adenosine signature cancers expected 1H 2022; translational research programmes for patient selection ongoing
  • Entered into third collaboration with Bill & Melinda Gates Foundation that added portfolio of up to five antiviral small molecule drug candidates and accelerated developmentof SARS-CoV-2 lead programme

Strengthened balance sheet providing several years of cash runway to deliver AI-designed molecules and accelerate pipeline growth

- Expect between $75.0-$85.0 million in cash inflows from collaborations for full year 2021

- In October, closed $510.4 million gross aggregate financing, consisting of $350.4 million gross proceeds from upsized initial public offering and $160.0 million gross proceeds from concurrent private placement

- Cash at the end of the third quarter 2021, adjusted to include the net proceeds from the initial public offering completed on October 5, 2021, was $783.7 million

Expanding drug discovery and automation laboratories to scale capacity and operations

- Opened 21,000-square foot expansion of facilities at Oxford Science Park

- Building 26,000-square foot laboratory in Milton Park, Oxfordshire focused on the automation of chemistry and biology to accelerate drug discovery

- Building 50,000-square foot precision medicine centre of excellence in Vienna, Austria

- Added to U.S. footprint with expansion in Miami, opening of office in Boston, and key hires in strategic operations, technology and chemistry

“Exscientia is leading the modernisation of how new medicines are created by using AI in each step of discovery and development. Demonstrating our unique translational capabilities, we recently published groundbreaking results showing our AI precision medicine platform can improve outcomes for cancer patients. We have also propelled our pipeline through substantial investment in our own new medicine programmes, significantly expanded our relationship with Bristol Myers Squibb, and added a portfolio of pandemic preparedness antivirals to our work with the Bill and Melinda Gates Foundation. Finally, we began expanding our labs, investing in scaling our precision medicine platform and automated synthesis and screening,” said Andrew Hopkins, DPhil., Exscientia’s founder and CEO. “We have incredible momentum, and with our solid balance sheet post IPO, we will continue investing in innovation that can enable the rapid translation of today’s most promising science into tomorrow’s best possible medicines.”

Investor Call and Webcast Information

Exscientia will host a conference call on November 18 at 1:30 p.m. GMT / 8:30 a.m. ET. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 760 294 1674 (U.S.), +44 203 059 5869 (U.K.), +44 203 059 8128 (International) and mentioning Exscientia. A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website.

Third Quarter Financial Results

For the convenience of the reader, the Company has translated pound sterling amounts to U.S. dollars at the rate of £1.000 to $1.347, which was the noon buying rate of the Federal Reserve Bank of New York on September 30, 2021.

Revenue: Revenue for the nine months ended September 30, 2021, was $31.3 million, an increase of $23.6 million compared to the nine months ended September 30, 2020, primarily due to the achievement of the opt-in milestone on the first candidate in-licensed on Exscientia’s collaboration with BMS.

R&D and cost of drug discovery: Due to various collaboration structures, R&D expenses may be included under multiple accounting line items. The tables below show how these expenses are separated across the accounting categories.

Three months ended September 30, 2021 ($ millions):

COGS

R&D

Share of

JV loss

Total

Partnered Programmes

6.5

––

––

6.5

Co-owned Programmes

––

1.0

0.3

1.4

Internal Pipeline and Technology Development

––

16.4

––

16.4

Total

6.5

17.4

0.3

24.2

Nine months ended September 30, 2021 ($ millions):

COGS

R&D

Share of

JV loss

Total

Partnered Programmes

16.6

––

––

16.6

Co-owned Programmes

––

1.8

1.3

3.1

Internal Pipeline and Technology Development

––

32.3

––

32.3

Total

16.6

34.1

1.3

52.0

General and administrative expenses: G&A expenses for the nine months ended September 30, 2021 were $26.1 million, or 34% of total operating expenses. For the nine months ended September 30, 2021, G&A expenses grew by $20.2 million compared to the nine months ended September 30, 2020, primarily associated with both an expansion of internal capabilities as well as transaction-related professional services.

Financial Outlook for 2021 & 2022

For the first three quarters of 2021, Exscientia announced three new partnerships and received $65.4 million cash inflows from its collaborations. The Company expects to receive a total of $75.0-$85.0 million by year-end 2021, and anticipates 2022 cash inflows from collaborations will exceed 2021 cash inflows from collaborations. Exscientia expects to end 2021 with cash and cash equivalents between $745.0-$755.0 million.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in £millions, except per share data)

Three months ended

September 30,

Nine months ended

September 30,

2021

2020

2021

2020

Revenue

17.6

1.0

23.2

5.7

Cost of sales

(4.8)

(3.3)

(12.3)

(10.3)

Research and development expenses

(12.9)

(2.9)

(25.3)

(7.2)

General and administrative expenses

(8.6)

(1.5)

(19.4)

(4.4)

Operating expenses

(26.3)

(7.7)

(57.0)

(21.8)

Foreign exchange gains/(losses)

1.7

(2.4)

(1.2)

(0.9)

Other income

1.8

0.4

3.0

0.8

Operating loss

(5.3)

(8.7)

(32.0)

(16.2)

Finance income/(expense)

(0.1)

(0.0)

(0.1)

0.0

Share of loss on joint ventures

(0.2)

(0.4)

(1.0)

(0.9)

Loss on derivative financial instruments

(1.4)

––

––

––

Loss before taxation

(6.9)

(9.2)

(33.1)

(17.0)

Income tax benefit

1.9

0.8

4.0

1.5

Loss for the period

(5.1)

(8.4)

(29.1)

(15.6)

Net loss per share

(0.06)

(0.08)

(0.32)

(0.15)

CONSTANT CURRENCY CONVERSION (unaudited)
(in $ millions, except per share data, at the rate of £1.000 to $1.347)

Three months ended

September 30,

Nine months ended

September 30,

2021

2020

2021

2020

Revenue

23.8

1.3

31.3

7.7

Cost of sales

(6.5)

(4.5)

(16.6)

(13.8)

Research and development expenses

(17.4)

(3.8)

(34.1)

(9.7)

General and administrative expenses

(11.6)

(2.0)

(26.1)

(6.0)

Operating expenses

(35.5)

(10.4)

(76.8)

(29.4)

Foreign exchange gains/(losses)

2.2

(3.2)

(1.7)

(1.2)

Other income

2.4

0.5

4.0

1.1

Operating loss

(7.1)

(11.7)

(43.1)

(21.8)

Finance income/(expense)

(0.1)

(0.0)

(0.2)

0.0

Share of loss on joint ventures

(0.3)

(0.6)

(1.3)

(1.2)

Loss on derivative financial instruments

(1.8)

––

––

––

Loss before taxation

(9.3)

(12.3)

(44.6)

(22.9)

Income tax benefit

2.5

1.1

5.3

2.0

Loss for the period

(6.8)

(11.3)

(39.3)

(21.0)

Net loss per share

(0.08)

(0.11)

(0.43)

(0.20)

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of development of candidate molecules, timing and progress of, and data reported from, clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding its projected revenue and cash runway. Any statement describing Exscientia’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on the Company’s business, and including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Registration Statement on Form F-1, filed with the Securities and Exchange Commission (SEC) on September 10, 2021, as amended (File No. 333-259431), and other filings that Exscientia makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors:
Sara Sherman
investors@exscientia.ai

Media:
Amanda Galgay
media@exscientia.ai

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TMD Security Launches Next Generation Key-less Lock Solutions for ATM Safe, Top Box and Access Doors30.11.2021 07:00:00 CET | Press release

TMD Security, global leader in high security ATM and branch access management, announced today the launch of its in-house R&D developed intelligent lock solutions for all types of access points. TMD key-less lock solutions for ATMs and access doors are integrated into TMD High Security Access Management which centrally manages all users and locations with one process and a real-time audit trail. Access for service engineers, branch staff and Cash-in-Transit (CIT) teams is scheduled and pre-approved. At the time of access, user and lock credentials are instantly checked and if correct, an encrypted One Time Code (OTC) is sent directly to the lock via the mobile app. TMD ATM safe lock is unique because the security and intelligence are inside the Lock Controller, located inside the safe behind the door. The OTC is sent directly to the Lock Controller via the mobile app. With no need for a keypad, the Lock Controller is an ‘invisible’ lock for the safe or access door. TMD’s user-friendly

Vifor Pharma announces changes to the Executive Committee as CFO retires30.11.2021 07:00:00 CET | Press release

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021 at his own request. Vifor Pharma is currently in the recruiting process for the new Chief Financial Officer, to be announced once the successor has been identified. Abbas Hussain, Chief Executive Officer of Vifor Pharma, commented: "On behalf of the company I would like to thank Colin for his valuable contributions and leadership during his tenure at Vifor Pharma. For his next phase of his life I wish him all the best and satisfaction in his future endeavors.” About Vifor Pharma Group Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with sev

Wemade Holds Spectacular Event to Celebrate 100 Days Since Global Launch of MIR430.11.2021 03:34:00 CET | Press release

Wemade’s masterpiece mobile MMORPG ‘MIR4’ will hold a spectacular event starting on November 30th, to celebrate the 100th day of its global release. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005798/en/ Wemade’s masterpiece mobile MMORPG ‘MIR4’ holds a spectacular event starting on November 30th, to celebrate the 100th day of its global release. It will be held for two weeks and special rewards will be given including Divine Dragon’s Blessing, Enhancement Stones, Summoning Tickets, and a special box containing various materials. While hunting monsters on the Mir continent, players can obtain Dragon Fruits. In addition, Wayfarer Travel tickets will be updated that allow for transfers to a different server. New Spirits will also be updated including Bloodtip Drago, a legendary-grade fire element Spirit, and Leocrat Khun, an epic-grade earth element Spirit. To commemorate the release of new spirits, a Spirit Special S

LabGenius Appoints Dr. Gino Van Heeke as Chief Scientific Officer30.11.2021 01:00:00 CET | Press release

LabGenius, the machine learning (ML)-driven protein engineering company, today announced the appointment of Gino Van Heeke Ph.D. as Chief Scientific Officer (CSO). In this role, Gino will leverage his wealth of drug discovery and development experience to direct LabGenius’ scientific strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005436/en/ Dr. Gino Van Heeke Appointed as LabGenius' CSO (Photo: Business Wire) “I’m extremely pleased to welcome Gino to the company as CSO,” said Dr. James Field, Founder and CEO of LabGenius. “Gino is an accomplished scientific leader with an impressive track record of successfully advancing drug candidates into pre-clinical and clinical development.” Gino joins LabGenius from Engitix Therapeutics, where, as CSO, he established a portfolio of projects and initiated the company’s first drug discovery campaign. Before this, Gino was Senior Director, Discovery and Early Development

InVeris Training Solutions Unveils SRCE™ – a Revolutionary, Augmented Reality Training System29.11.2021 20:00:00 CET | Press release

InVeris Training Solutions, the leading provider of integrated live-fire and virtual weapons training systems for military, law enforcement agencies and commercial shooting ranges, today unveils SRCE™ (See, Rehearse, Collectively Experience or "Source"), a groundbreaking, augmented reality-based, untethered weapons training simulator. InVeris Training Solutions provides the most advanced augmented reality technology available in a military and law enforcement training simulator, a feat previously thought to be years away by many in the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005628/en/ SRCE is the only untethered AR training solution on the market—allowing up to 4 participants to train with simulated weapons and tactical gear. (Photo: Business Wire) "Augmented reality delivers the best of the virtual and real worlds in a way that's fully lifelike, seamless, customizable and economical," said InVeris CE

Verimatrix Launches Streamkeeper To Offer Industry’s First Battle-Ready Cybersecurity Solution Engineered to Hunt Down and Take Out Video Piracy29.11.2021 17:45:00 CET | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced the launch of its new Verimatrix StreamkeeperSM solution, a cybersecurity and anti-piracy gamechanger for the media & entertainment industry. Streamkeeper empowers customers to hunt down and take out OTT pirates who steal content such as live sports and premium movie as they are distributed from the source to the endpoint (mobile app/user level). The solution includes Verimatrix's all-new CounterspySM technology -- the autonomous injection of an anti-piracy and app protection security agent that utilizes the company’s proprietary zero code technology which allows customers to add deep, defensive countermeasures, plus monitor their clients without the hassle of a huge integration effort. Integration efforts have also been reduced dramatically, from months to minutes, accompanying numerous operator benefits ranging from a reducti

Introducing ThreatConnect 6.4 - Improving Threat Intelligence Processes and SOC Metrics29.11.2021 17:31:00 CET | Press release

ThreatConnect Inc.®, the leader in enabling a risk led and intelligence-driven security is announcing ThreatConnect 6.4, which introduces new capabilities that allow security operations and cyber threat intelligence (CTI) analysts to get useful context faster during investigations and to better measure team efficiencies. ThreatConnect combines its Threat Intelligence Platform (TIP) and Security Orchestration and Automation platform (SOAR), creating a continuous feedback loop that helps make Intelligence-Driven Operations a reality. This latest product release builds upon the foundation of Intelligence-Driven Operations, empowering the workflow of threat intelligence and security operations teams individually and together. The 6.4 release helps CTI and security operations center (SOC) teams get more context quickly, enabling faster investigations for both. CTI teams are enabled to more easily build and maintain a dynamic threat library, while updated dashboards allow SOC and IR leaders